DONGSUNG PHARMACEUTICAL CO.,LTD

동성제약(주) · KOSPI: 002210 · Pharmaceuticals and medicinal chemicals

Key facts

Korean name: 동성제약(주)
Market / ticker: KOSPI · 002210
Industry: Pharmaceuticals and medicinal chemicals
Established: 1957-11-25
Fiscal year ends: December
Website: dongsung-pharm.co.kr
DART corp code: 00116268
Latest revenue: ₩87.2B (FY2025)

Items worth checking

high

Total equity was below share capital at FY2025 end (12% capital impairment).

Source: Annual report FY2025

high

Auditor opinion for Term 67 (two years prior): Qualified.

Source: Annual report FY2025

high

Listing status issue disclosed — filed 2026-07-15.

Source: Other market notice

high

Unfaithful disclosure designation — filed on 4 separate dates in the last 12 months, latest 2026-07-15.

Source: Designated for unfaithful disclosure

high

Alleged embezzlement / breach of trust disclosed — filed 2026-06-23.

Source: Alleged embezzlement / breach of trust

high

Court rehabilitation / bankruptcy proceeding disclosed — filed on 3 separate dates in the last 12 months, latest 2026-05-15.

Source: 회생절차종결결정

medium

Liabilities were 621% of equity at FY2025 end.

Source: Annual report FY2025

medium

Operating loss in both FY2024 and FY2025.

Source: Annual report FY2025

medium

Litigation filed or ruled — filed on 17 separate dates in the last 12 months, latest 2026-09-14.

Source: Litigation ruling

medium

Decision to issue convertible / warrant / exchangeable bonds — the filing states whether new or treasury shares back it — filed 2026-04-01.

Source: Material event report — Convertible bond issuance decision

medium

Filing on change of largest shareholder or control — filed on 2 separate dates in the last 12 months, latest 2026-04-01.

Source: Change in shareholdings of largest shareholder — Change of largest shareholder

medium

Capital reduction decided — filed 2026-03-31.

Source: Material event report — Capital reduction decision

low

Filing on a change in the CEO line-up — filed on 3 separate dates in the last 12 months, latest 2026-04-15.

Source: Change of CEO (notice)

low

Decision on paid-in capital increase (share dilution) — filed 2026-03-27.

Source: Material event report — Paid-in capital increase (rights offering) decision

Financial summary

KRW	FY2023	FY2024	FY2025
Revenue	₩88.6B	₩88.4B	₩87.2B
Operating income	₩665M	−₩5.7B	−₩10.1B
Net income	−₩6.0B	−₩14.6B	−₩25.7B
Total assets	₩111.0B	₩140.7B	₩168.4B
Total liabilities	₩75.1B	₩96.7B	₩145.1B
Total equity	₩35.9B	₩44.0B	₩23.4B
Share capital	₩26.1B	₩26.1B	₩26.6B

Separate statements · FY2025 operating margin -11.6% · liabilities to equity 621% · Annual report FY2025 (Korean original)

Auditor opinions

Period	Auditor	Opinion
Term 69 (current)	한울회계법인	Unqualified
Term 68 (prior)	한울회계법인	Unqualified
Term 67 (two years prior)	한영회계법인	Qualified

Largest shareholder history

Date	Largest shareholder (Korean)	Stake	Cause (Korean)
2025년 04월 21일	(주)브랜드리팩터링	—	前최대주주 이양구와 (주)브랜드리팩터링의 장외 매도 및 매수
2025년 06월 27일	(주)브랜드리팩터링	—	장내거래로 인한 변동
2025년 06월 27일	(주)브랜드리팩터링	—	장외거래로 인한 변동

Recent filings

Date	Filing	Original
2026-09-14	Litigation ruling	DART
2026-08-27	Large business group status disclosure	DART
2026-08-18	Amended: Half-year report (2026.06)	DART
2026-08-14	Half-year report (2026.06)	DART
2026-08-14	Payment terms to suppliers and dispute mediation body	DART
2026-07-29	Other management matter (voluntary)	DART
2026-07-29	Other market notice	DART
2026-07-15	Other market notice	DART
2026-07-15	Designated for unfaithful disclosure	DART
2026-06-23	Other market notice	DART
2026-06-23	Designated for unfaithful disclosure	DART
2026-06-23	Alleged embezzlement / breach of trust	DART
2026-06-04	Amended: Large business group status disclosure	DART
2026-06-01	Attachment added: Corporate governance report	DART
2026-06-01	Large business group status disclosure	DART
2026-05-22	Other market notice	DART
2026-05-20	Other notice (notice)	DART
2026-05-15	Amended: Record date / shareholder register closure set	DART
2026-05-15	Amended: Resolution to convene shareholders meeting	DART
2026-05-15	회생절차종결결정	DART

Showing the 20 most recent of 120 filings. The full brief lists all of them.

Full brief on DONGSUNG PHARMACEUTICAL CO.,LTD — $39

Every filing from the last 12 months in English, not just the 20 most recent — each linked to its Korean original
Latest half-year and quarterly figures on top of the three annual years, plus the full auditor and largest-shareholder history
Any KOSPI, KOSDAQ or KONEX company, not just the ones listed here — delivered as a private link the moment payment clears

Get the full brief

For business customers. EU companies: enter your VAT number at checkout and no VAT is charged (reverse charge).

Other Korean companies in Pharmaceuticals and medicinal chemicals

AHN-GOOK PHARMACEUTICAL Co., Ltd. KOSDAQ 001540
Aprogen Biologics Inc. KOSPI 003060
Aprogen, Inc KOSPI 007460
Boryung Corporation KOSPI 003850
BUKWANG PHARMACEUTICAL IND CO.,LTD KOSPI 003000
CHONGKUNDANG HOLDINGS CORP. KOSPI 001630

Data generated 2026-09-16 from OpenDART.

This page summarizes public filings from DART, the official electronic disclosure system of Korea. It is not investment, credit or legal advice. Figures are shown in the currency the company reports in. Titles and labels are machine-translated and may contain errors — always check the linked original filing. Source: OpenDART, Financial Supervisory Service, Korea.